CELL/TISSUE CULTURE SUPPLIES

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations I-1
• Disclaimers I-2
• Data Interpretation & Reporting Level I-2
• Quantitative Techniques & Analytics I-2
• Product Definitions and Scope of Study I-3
• Cell/Tissue Culture Media, Sera and Reagents I-3

II. EXECUTIVE SUMMARY

1. Market Dynamics II-1

• Outlook II-1
• Biopharmaceutical Drugs Fuel Cell Culture Market II-1
• Market Scenario II-2
• Industrial vs. Academic II-2
• Segmental Outlook II-2
• Regional Perspective II-3
• Market Structure II-3
• Leading Players II-3
• Table 1: Leading Players in US Cell/Tissue Culture Market (2003, 2004, & 2005E): Percentage Breakdown of Value Sales for Invitrogen, JRH Biosciences, Hyclone, Cambrex Bio Science Walkersville (Formerly BioWhittaker), Sigma-Aldrich, and Others (includes corresponding Graph/Chart) II-3

2. Trends and Issues II-4

• Surging Demand for Cell Culture Products II-4
• Changing Trend Towards Serum-Free Media II-4
• Proteomics and Pharmacokinetics Drive Market Growth II-4
• CHO, Hybridomas and Mabs Dominate Mammalian Cell Culture II-6
• Sluggish Fetal Bovine Serum Market II-6
• Cell Therapy Market Witnesses Increasing Consolidation Activity II-6
• Specialty Media Growing in Demand II-6
• Emerging Alternatives to Conventional Serum Supplemented Media II-7
• Growth of Defined Media II-7
• Regulations Prompt Change in Trends II-7
• Media Optimization II-7
• Other Trends II-8
• Manufacture-on-Demand: Gaining Momentum II-8
• Move Towards Contract Manufacturing II-8
• Factors Impacting Growth II-8
• Business Models Driving the Need for Contract Manufacturing II-9
• Trends in Contract Manufacturing II-9
• Target Sectors for Contract Manufacturers II-9

3. End Use Analysis II-10

• End Use Applications II-10
• Cell Therapy II-10
• Growing by Leaps and Bounds II-10
• Cell Therapy Applications II-11
• Key Factors Affecting the Cell Therapy Market II-11
• Future Trends II-11
• Related Market Sectors II-11
• Progenitor Cell Therapy II-11
• Table 2: US Market for Progenitor Cell Therapy (2003 & 2004): Annual Sales in US$ Million for Blood Cells; Skin, Bone and Cartilage; and Others (includes corresponding Graph/Chart) II-12
• Table 3: US Market for Progenitor Cell Therapy (2003 & 2004): Percentage Breakdown by Value Sales for Blood Cells; Skin, Bone and Cartilage; and
• Others (includes corresponding Graph/Chart) II-12
• Stem Cell Therapy II-12
• Scope and Applications II-13
• Other Related Technologies II-13
• Somatic Cell Nuclear Transfer (SCNT) II-13
• Tissue Engineering II-13
• End Use Industries II-13

4. Cell/Tissue Culture: Physiological Overview II-14

• Introduction II-14
• History II-14
• Plant Cell and Tissue Culture (PCTC) II-18
• Cell/Tissue Culture Media, Sera and Reagents II-21
• Classical Media II-21
• Specialty Media II-22
• Serum II-22
• Fetal Bovine Serum II-22
• Serum-Free Media II-22
• Cell Culture Reagents II-22
• Role of Tissue Culture in the Growth of Cell Types II-23
• Equipment II-23
• Storage and Preservation II-23
• Maintenance II-23
• Growth Pattern II-24
• Harvesting II-24
• Media and Growth Requirements II-24
• Physiological Parameters II-24
• Medium Requirements (Often Empirical) II-25
• Feeding II-25
• Safety Precautions II-25
• Methods of Tissue Culture II-25
• Preparation of Media II-25
• Growth and Morphology II-26
• Sub Culturing Adherent Cells II-26
• Trypsin-EDTA II-26
• EDTA Alone II-26
• Thawing Frozen Cells II-26
• Freezing Cells II-26
• Cell Culture Contamination - A Looming Problem II-27
• Classification II-27
• Major Cell Culture Contaminants II-27
• Chemical Contamination II-27
• Types and Sources of Potential Chemical Contaminants II-27
• Varied Sources of Chemical Contamination II-28
• Media and Components II-28
• Sera II-28
• Water II-28
• Storage Vessels II-29
• Fluorescent Lights II-29
• Endotoxins II-29
• Incubators II-30
• Biological Contamination II-30
• Varied Sources of Biological Contamination II-30
• Mycoplasmas II-31
• Airborne Particles and Aerosols II-31
• Cross Contamination by Other Cell Cultures II-31
• Consequences/Problems of Contamination II-31
• Controlling Cell Culture Contamination II-32
• Measures Aimed at Reducing Contamination Problems II-32
• 5. Regulatory Environment II-33

6. Product Introductions/Innovations II-34

• HyClone Introduces HyQ®CDM4MAb™ for Hybridoma Cell Lines II-34
• INTEGRA Biosciences Adds Alarm Interface to CELLROLL and CELLSPIN Systems II-34
• Nikon Launches New Imaging and Tracking Systems for Cell Culture II-34
• Genetix Develops Cell Dispenser II-34
• SAFC Biosciences Introduces LONGTMR3IGF-I for Industrial Cell Culture II-34
• Biocrystal Presents Opticell II-35
• TAP Unveils CompacT SelecT™ II-35
• New Brunswick Scientific Augments New Products to Cell Culture Systems II-35
• Cell Culture Technologies Develops Fortified Production Media II-35
• HyClone Unveils New Microcarrier Product Line -HyQ®Spheres™ II-35
• Celliance Brings Out LucraTone(TM) Peptones II-35
• Millipore Offers More Products for Cell Culture Assays II-36
• FibraStage™ Cell Culture System for Higher Yields II-36
• Acolyte to Incorporate AK Rapid® technology BacLite RapiTECT™ Range II-36
• Ventria Bioscience Unveiled Lacromin™ for Cell Culture Media II-36
• Vivascience Launches Vivadish II-36
• Celliance Corporation Unveils Hybri-CYTE(TM) II-37

7. Recent Industry Activity II-38

• SAFC-Biosciences Forms to Support Sigma-Aldrich II-38
• Invitrogen and Cellartis to Co-develop hESC
• Reporter Lines II-38
• CELLCA and Rentschler Join Forces for Unique
• High-Level Expression System II-38
• ArcDia Partners with Chip-Man Technologies II-38
• Chugai Pharmaceutical Receives License for Cell Line from Cambrex Bio Science Walkersville, Inc. II-38
• Chemicon Inks Distribution Agreement with CELLnTEC II-39
• Chemicon Signs an Agreement with ReNeuron II-39
• Chemicon to Market Stem Cell Products of ASCC II-39
• SCS and Chemicon Introduce ESGRO
• Complete™ Product Range II-39
• Serologicals Acquires Cytomyx Ltd II-39
• Millipore to Take Over Serologicals II-40
• CAT Opts SelectT™ for Higher Cell Culture Yields II-40
• SAFC to Market Cell Line Engineering of ProBioGen II-40
• Chemicon Licensed to Employ the RheoSwitch(R) System of RheoGene II-40
• SCS and Chemicon Sign an Agreement for ES Cell Media II-40
• Innovata Grants UCOE Gene Expression Technology to Celliance II-40
• Chemicon and Axordia Collaborate for New Antibody Markers II-41
• Genzyme Acquires Verigen AG II-41
• Chemicon Acquires Specialty Media II-41
• CalbaTech Pockets K-D Medical II-41
• Sigma- Aldrich Acquires JRH Biosciences II-42
• Invitrogen Acquires Dynal II-42
• Invitrogen Takes Over Biosource International II-42
• CellzDirect Takes Over HepatoTech II-42
• BD Acquires Atto Biosciences II-43
• Serologicals Corp Pockets AltaGen Biosciences II-43
• Serologicals Purchases Upstate Group II-43
• The Automation Partnership (TAP) Collaborates with MAIA SCIENTIFIC II-43
• Cambrex Bio Science signs agreement with QBM Cell Science II-43
• Serologicals Forms Celliance II-44
• JRH Biosciences Opens cGMP Facility II-44
• Vitrolife Bags Patent Approvals in the US and Europe II-44
• C3 Receives Clearance from Japanese Ministry
• of Health II-44
• Fisher Scientific Acquires Perbio Science II-44
• ICN Pharmaceuticals Divests Biomedicals Division II-45
• Boston Scientific Enters Into a Strategic Alliance with Osiris II-45
• Perbio Acquires FBS Supplier in Australia II-45
• BD Biosciences Collaborates with Harvard Institute of Proteomics II-45
• Serologicals in Global Distribution Agreement with Novo Nordisk II-45
• Invitrogen in Licensing Agreement for CHO Cell Lines II-46
• CMT Unveils New Facility at Pennsylvania II-46
• Serologicals Corp Acquires Intergen Co II-46
• Cambrex Acquires Bio Science Corp II-47
• Anthrogenesis Acquires Atlantic Stem Cells II-47
• Celmed Acquires NeuroGenomics and NeuroGeneration II-47
• HyClone and Kinetics Form HyNetics LLC II-47
• Aastrom Biosciences Enters Into a Co-MarketingAgreement With Bio Whittaker II-47
• Vitrolife Enters Into a Co-operation Agreement with Millenium II-48
• Perbio Acquires Pierce & Warriner II-48
• Sigma-Aldrich Acquires Ark Scientific II-48
• Sigma-Aldrich and Ajinomoto Enter Into Amino Acid
• Alliance II-48SeraCare Inc. and Grupo Grifols Enter Into Plasma Supply Agreement II-49
• Commonwealth Biotechnologies and Kemp
• Biotechnologies Sign Letter of Intent II-49
• Perbio Science Inks Agreement with Panymex International II-49
• Perbio' s HyClone Laboratories Inks Agreement with China Northwestern Minorities University II-49
• Perbio' s Cell Culture Division Signs Agreement with ConAgra II-49
• Serologicals Expands BSA Manufacturing Facility II-49
• Invitrogen Corporation Undergoes Restructuring II-50
• Serologicals Divests Seramed to Aventis II-50
• SeraCare Inc. Divests Consolidated Technologies II-50

8. Focus on Select Major Players II-51

• AMRESCO Inc (USA) II-51
• Analytical Biological Services (USA) II-51
• BD Biosciences (USA) II-51
• Cambrex Bio Science Walkersville, Inc (USA) II-51
• Cell Culture Technologies (Switzerland) II-52
• Cell Essentials (USA) II-52
• MP Biomedicals (USA) II-52
• Invitrogen (USA) II-52
• Irvine Scientific (USA) II-53
• JRH Biosciences (USA) II-53
• Kemp Biotechnologies (USA) II-53
• Mediatech Inc. (USA) II-53
• Medi-Cult (Denmark) II-54
• PerBio Science (Sweden) II-54
• PromoCell (Germany) II-54
• Sera Laboratories International (UK) II-54
• Serologicals Corp (USA) II-55
• Sigma-Aldrich (USA) II-55
• SAFC Biosciences (USA) II-55
• USB Corp (USA) II-55
• Vitrolife AB (Sweden) II-56
• Wisent Inc. (Canada) II-56

9. Global Market Perspective II-57

• Table 4: World Recent Past, Current & Future Market Analysis for Cell/Tissue Culture Supplies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) & Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-57
• Table 5: World 10-Year Perspective for Cell/Tissue Culture Supplies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) & Latin America Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) II-57
• Table 6: World Recent Past, Current & Future Market Analysis for Media Cell/Tissue Culture Supplies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) & Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-58
• Table 7: World 10-Year Perspective for Media Cell/Tissue Culture Supplies by Geographic Region - Percentage Breakdown of Dollar Sales for US,
• Canada, Japan, Europe, Asia-Pacific (excluding Japan) & Latin America Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) II-58
• Table 8: World Recent Past, Current & Future Market Analysis for Sera Cell/Tissue Culture Supplies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) & Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includescorresponding Graph/Chart) II-59
• Table 9: World 10-Year Perspective for Sera Cell/Tissue Culture Supplies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) & Latin America Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) II-59
• Table 10: World Recent Past, Current & Future Market Analysis for Reagent Cell/Tissue Culture Supplies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) & Latin America Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-60
• Table 11: World 10-Year Perspective for Reagent Cell/Tissue Culture Supplies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) & Latin America Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) II-60

II. MARKET

<>1. The United States III-1

• A. Market Analysis III-1
• Biotech Industry in the US III-1
• Cell & Tissue Culture Market III-1
• A Brief Insight III-1
• Grade Definitions III-2
• Market Trends III-2
• Trend Towards Serum-Free Media III-2
• Table 12: US Market for Cell Culture (2004): Percentage Breakdown of Value Sales for Media, Sera and Reagents by End Use Application - Industrial and Academic (includes corresponding Graph/Chart) III-3
• Table 13: US Market for Cell Culture (2004): Percentage Breakdown of Value Sales by Industrial and Academic End Use Application for Liquid Media, Powdered Media, Fetal Bovine Serum, Serum-free and Protein-free Media, Growth Factors, Other Sera, Supplements, Antibiotics, and Other Products (includes corresponding Graph/Chart) III-4
• Liquid and Powdered Media Account for Major Share III-4
• Fetal Bovine Serum - Uses on a Decline III-4
• Table 14: Leading Producers of Fetal Bovine Serum in the US (2004): Percentage Breakdown of Value Sales for Life Technologies, Hyclone, and Others (includes corresponding Graph/Chart) III-5
• Bovine Serum Industry: Highly Unpredictable III-5
• Suppliers Searching for New Areas III-5Sustained Rise of Serum-Free and Protein- Free Media III-5
• Rise in Cell Culture Equipment Demand Leads to Innovation III-5
• End Use Analysis III-6
• Table 15: US Market for Cell and Tissue Culture (2004): Percentage Share by Research Application for Cellular Research, Protein Expression, Protein Production, Cell Therapy, and Cell Transplantation (includes corresponding Graph/Chart) III-6
• Table 16: US Market for Cell Culture Reagents (2004): Percentage Breakdown of Value Sales for End Use Applications- Academic, Industrial, and Non-Academic (includes corresponding Graph/Chart) III-6
• Table 17: Leading Players in US Cell/Tissue Culture Market (2003, 2004, & 2005E):Percentage Breakdown of Value Sales for Invitrogen, JRH Biosciences, Hyclone, Cambrex Bio Science Walkersville (Formerly BioWhittaker), Sigma-Aldrich, and Others (includes corresponding Graph/Chart) III-7
• Factors Influencing the Market for Tissue and Cell Culture Media III-7
• Regulatory Controls III-7
• Guidelines Governing Use of Cell/Tissue Culture Reagents III-8
• MSDS and Hazardous Information III-8
• Toxic Substances Control Act III-8
• Key Players III-8
• AMRESCO Inc III-8
• Analytical Biological Services III-8
• BD Biosciences III-9
• Cell Applications Inc III-9
• Cell Essentials III-9
• Cambrex Bio Science Walkersville, Inc III-9
• MP Biomedicals (USA) III-10
• Invitrogen III-10
• Irvine Scientific III-10
• Mediatech Inc III-11
• Serologicals Corp III-11
• Sigma-Aldrich III-11
• SAFC Biosciences III-11
• USB Corp III-12
• Product Introductions/Innovations III-12
• Strategic Developments III-16
• B. Market Analytics III-24
• Table 18: US Recent Past, Current & Future Analysis for Cell/Tissue Culture Supplies by Product Segment -Media, Sera, and Reagents Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-24
• Table 19: US 10-Year Perspective for Cell/Tissue Culture Supplies by Product Segment - Percentage Breakdown of Dollar Sales for Media, Sera, and Reagents Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-24

2. Canada III-25

• A. Market Analysis III-25
• Overview III-25
• Biotechnology Industry III-25
• Wisent Inc - A Key Player III-25
• Strategic Developments III-25
• B. Market Analytics III-26
• Table 20: Canadian Recent Past, Current & Future Analysis for Cell/Tissue Culture Supplies by Product Segment - Media, Sera, and Reagents Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-26
• Table 21: Canadian 10-Year Perspective for Cell/Tissue Culture Supplies by Product Segment - Percentage Breakdown of Dollar Sales for Media, Sera, and Reagents Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-27

3. Japan III-28

• A. Market Analysis III-28
• Cell and Tissue Culture Market III-28
• Biotechnology Industry in Japan III-28
• Strategic Development III-28
• B. Market Analytics III-29
• Table 22: Japanese Recent Past, Current & Future Analysis for Cell/Tissue Culture Supplies by Product Segment - Media, Sera, and Reagents Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-29
• Table 23: Japanese 10-Year Perspective for Cell/Tissue Culture Supplies by Product Segment - Percentage Breakdown of Dollar Sales for Media, Sera, and Reagents Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-29

4. Europe III-30

• A. Market Analysis III-30
• Biotech and Life-Science Research III-30
• Market Overview III-30
• B. Market Analytics III-31
• Table 24: European Recent Past, Current & Future Analysis for Cell/Tissue Culture Supplies by Geographic Region - France, Germany, UK, Italy & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-31
• Table 25: European Recent Past, Current & Future Analysis for Cell/Tissue Culture Supplies by Product Segment - Media, Sera, and Reagents Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-32
• Table 26: European 10-Year Perspective for Cell/Tissue Culture Supplies by Geographic Region - Percentage Breakdown of Dollar Sales for France,
• Germany, UK, Italy & Rest of Europe Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-32
• Table 27: European 10-Year Perspective for Cell/Tissue Culture Supplies by Product Segment - Percentage Breakdown of Dollar Sales for Media, Sera,
• and Reagents Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-33

4a. France III-34

• A. Market Analysis III-34
• B. Market Analytics III-34
• Table 28: French Recent Past, Current & Future Analysis for Cell/Tissue Culture Supplies by Product Segment - Media, Sera, and Reagents Markets
• Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-34
• Table 29: French 10-Year Perspective for Cell/Tissue Culture Supplies by Product Segment - Percentage Breakdown of Dollar Sales for Media, Sera,
• and Reagents Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-35

4b. Germany III-36

• A. Market Analysis III-36
• Biotech Research Scenario III-36
• Table 30: German Biotech Market: Percentage Share in 2004 by Application Area for Environment, Human Health Care, Chemical industry, Food, Agriculture, Energy, and Others (includes corresponding Graph/Chart) III-37
• PromoCell - A Key Player III-37
• Strategic Developments III-37
• B. Market Analytics III-39
• Table 31: German Recent Past, Current & Future Analysis for Cell/Tissue Culture Supplies by Product Segment - Media, Sera, and Reagents Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-39
• Table 32: German 10-Year Perspective for Cell/Tissue Culture Supplies by Product Segment - Percentage Breakdown of Dollar Sales for Media, Sera, and Reagents Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-40

4c. The United Kingdom III-41

• A. Market Analysis III-41
• Cell and Tissue Culture Market III-41
• Biotechnology Industry - A Brief Insight III-41
• Research Entities III-41
• Commercial Activities III-41
• Outlook III-41
• Regulatory Issues III-42
• HFE Act Guidelines III-42
• The Ethical Issues III-42
• Sera Laboratories International- A Key Player III-43
• Strategic Corporate Developments III-43
• Product Launches III-43
• B. Market Analytics III-44
• Table 33: UK Recent Past, Current & Future Analysis for Cell/Tissue Culture Supplies by Product Segment - Media, Sera, and Reagents Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-44
• Table 34: UK 10-Year Perspective for Cell/Tissue Culture Supplies by Product Segment - Percentage Breakdown of Dollar Sales for Media, Sera, and Reagents Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-44

4d. Italy III-45

• A. Market Analysis III-45
• B. Market Analytics III-45
• Table 35: Italian Recent Past, Current & Future Analysis for Cell/Tissue Culture Supplies by Product Segment - Media, Sera, and Reagents Markets
• Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-45
• Table 36: Italian 10-Year Perspective for Cell/Tissue Culture Supplies by Product Segment - Percentage Breakdown of Dollar Sales for Media, Sera, and Reagents Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-46

4e. Rest of Europe III-47

• A. Market Analysis III-47
• Cell and Tissue Culture Market III-47
• Scenario in other European Countries III-47
• Key Players III-47
• Cell Culture Technologies (Switzerland) III-47
• Medi-Cult (Denmark) III-48
• PerBio Science (Sweden) III-48
• Vitrolife AB (Sweden) III-48
• Strategic Developments III-48
• B. Market Analytics III-51
• Table 37: Rest of Europe Market for Cell/Tissue Culture Supplies - Recent Past, Current & Future Analysis by Product Segment for Media, Sera, and Reagents Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-51
• Table 38: Rest of Europe 10-Year Perspective for Cell/Tissue Culture Supplies by Product Segment - Percentage Breakdown of Dollar Sales for Media, Sera
• and Reagent Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-51

5. Asia-Pacific III-52

• A. Market Analysis III-52
• Overview III-52
• India III-52
• China III-52
• Taiwan III-53
• Australia III-53
• Strategic Developments III-53
• B. Market Analytics III-55
• Table 39: Asia-Pacific Market for Cell/Tissue Culture Supplies - Recent Past, Current & Future Analysis by Product Segment for Media, Sera, and Reagents Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-55
• Table 40: Asia-Pacific 10-Year Perspective for Cell/Tissue Culture Supplies by Product Segment - Percentage Breakdown of Dollar Sales for Media, Sera and Reagent Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-55

6. Latin America III-56

• A. Market Analysis III-56
• Cell and Tissue Culture Market III-56
• Brazilian Biotech Industry III-56
• B. Market Analytics III-56
• Table 41: Latin American Market for Cell/Tissue Culture Supplies - Recent Past, Current & Future Analysis by Product Segment for Media, Sera, and Reagents Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-56
• Table 42: Latin American 10-Year Perspective for Cell/Tissue Culture Supplies by Product Segment - Percentage Breakdown of Dollar Sales for Media, Sera and Reagent Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart) III-57

IV. COMPETITION

• 1. Aastrom Biosciences, Inc. (USA) IV-1
• Table 43: Annual Sales Analysis: 2004-2006 (In US$ million) IV-2
• 2. ABgene (UK) IV-4
• 3. Acolyte Biomedica Limited (UK) IV-5
• 4. Advanced Biotechnologies, Inc. (USA) IV-7
• 5. American Type Culture Collection (USA) IV-10
• 6. Amphioxus Cell Technologies, Inc. (USA) IV-14
• 7. Amresco, Inc. (USA) IV-15
• 8. Analytical Biological Services, Inc. (USA) IV-16
• 9. Australian Stem Cell Centre (ASCC) (Australia) IV-17
• 10. Barloworld Scientific Ltd. (UK) IV-18
• Techne, Inc. (USA) IV-20
• R&D Systems, Inc. (USA) IV-22
• 11. Barnstead International (USA) IV-24
• 12. Becton Dickinson and Company (USA) IV-26
• Table 44: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-28
• Table 45: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-28
• Table 46: Annual Sales Analysis: 2004-2005 (In US$ million) IV-28
• BD Biosciences (USA) IV-31
• 13. Bellco Glass, Inc. (USA) IV-33
• 14. Biochrom AG (Germany) IV-33
• 15. Biocientifica SA (Argentina) IV-34
• 16. BioCrystal Limited (USA) IV-35
• 17. Biodesign International (USA) IV-37
• 18. Biohit PLC (Finland) IV-40
• Table 47: Annual Sales Analysis: 2004-2005 (In € million) IV-40
• Table 48: Annual Sales Analysis by Segment: 2004-2005 (In € million) IV-40
• 19. Biological Industries (Israel) IV-43
• 20. Biomedical Technologies, Inc. (USA) IV-44
• 21. Bio-Rad Laboratories, Inc. (USA) IV-46
• Table 49: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-47
• Table 50: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-48
• Table 51: Annual Sales Analysis: 2004-2005 (In US$ million) IV-48
• Table 52: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-48
• Table 53: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-48
• Table 54: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-48
• 22. Biotage LLC (USA) IV-53
• 23. Biowest (France) IV-54
• 24. Boston Scientific Corporation (USA) IV-56
• Table 55: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion) IV-58
• Table 56: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ billion) IV-58
• Table 57: Half Yearly Sales Analysis by Business Segment: 2005-2006 (H1) (In US$ billion) IV-58
• Table 58: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ billion) IV-58
• Table 59: Annual Sales Analysis: 2004-2005 (In US$ billion) IV-59
• Table 60: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ billion) IV-59
• Table 61: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-59
• Table 62: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion) IV-59
• 25. Brandtech Scientific, Inc. (USA) IV-69
• 26. Calbatech, Inc. (USA) IV-71
• Table 63: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-72
• Table 64: Annual Sales Analysis: 2004-2005 (In US$ million) IV-72
• 27. Cambrex Bio Science Walkersville (USA) IV-73
• 28. Cell Applications, Inc. (USA) IV-74
• 29. Cell Culture Technologies (Switzerland) IV-75
• 30. Cell Essentials, Inc. (USA) IV-77
• 31. Cell Sciences, Inc. (USA) IV-78
• 32. Cellartis AB (Sweden) IV-79
• 33. Cellca GmbH (Germany) IV-80
• 34. Cellntec Advanced Cell Systems AG (Switzerland) IV-81
• 35. Cellontech Co., Ltd. (Korea) IV-82
• 36. Cellzdirect, Inc. (USA) IV-83
• 37. Centerchem, Inc. (USA) IV-84
• 38. Chemicon International, Inc. (USA) IV-86
• 39. Chugai Pharmaceutical Co., Ltd. (Japan) IV-91
• Table 65: First Quarter Sales Analysis: 2005-2006 (In ¥ million) IV-91
• Table 66: Annual Sales Analysis: 2004-2005 (In ¥ million) IV-92
• 40. Clinical Cell Culture Ltd. (UK) IV-95
• 41. Commonwealth Biotechnologies, Inc. (USA) IV-97
• Table 67: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ thousands) IV-98
• Table 68: Half Yearly Sales Analysis by Operations: 2005-2006 (H1) (In US$ thousands) IV-98
• 42. Conception Technologies (USA) IV-101
• 43. Corning, Inc. (USA) IV-103
• Table 69: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, September) (In US$ million) IV-105
• Table 70: Nine Months Sales Analysis by Quarter: 2005-2006 (Nine Months Ended, September) (In US$ million) IV-105
• Table 71: Annual Sales Analysis: 2004-2005 (In US$ million) IV-105
• Table 72: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-105
• Table 73: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-106
• Table 74: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-106
• 44. Coy Laboratory Products, Inc. (USA) IV-110
• 45. CSL Biosciences (Australia) IV-111
• Table 75: Annual Sales Analysis: 2005-2006 (In A$ million) IV-111
• Table 76: Annual Sales Analysis by Geographic Region: 2005-2006 (In A$ million) IV-112
• 46. Digene Corporation (USA) IV-113
• Table 77: Nine Months Sales Analysis by Quarter: 2005-2006 (Nine Months Ended March) (In US$ million) IV-114
• Table 78: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-114
• 47. Don Whitley Scientific Ltd. (UK) IV-117
• 48. Drummond Scientific Co. (USA) IV-118
• 49. Essen Instruments (USA) IV-119
• 50. Fertipro NV (Belgium) IV-120
• 51. Gemini Bio-Products (USA) IV-121
• 52. Genetix Ltd. (UK) IV-123
• Table 79: Half Yearly Sales Analysis: 2005-2006 (H1) (In £ million) IV-123
• Table 80: Annual Sales Analysis: 2004-2005 (In £ million) IV-124
• 53. Genzyme Corporation (USA) IV-125
• Table 81: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-128
• Table 82: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-128
• Table 83: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-128
• Table 84: Annual Sales Analysis: 2004-2005 (In US$ million) IV-128
• Table 85: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-128
• Table 86: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-129
• Table 87: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion) IV-129
• 54. Globepharm Ltd. (UK) IV-134
• 55. Greiner Bio-One GmbH (Germany) IV-135
• 56. GroPep Limited (Australia) IV-138
• Table 88: Annual Sales Analysis: 2005-2006 (In A$ million) IV-140
• Table 89: Annual Sales Analysis by Business Segment: 2005-2006 (In A$ million) IV-140
• 57. Grupo Grifols (Spain) IV-142
• 58. Harvard Bioscience, Inc. (USA) IV-150
• Table 90: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-153
• Table 91: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-153
• Table 92: Annual Sales Analysis: 2004-2005 (In US$ million) IV-154
• Table 93: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-154
• Table 94: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-154
• 59. Imgenex Corporation (USA) IV-156
• 60. Integra Biosciences AG (Switzerland) IV-158
• 61. Invitrogen Corporation (USA) IV-159
• Table 95: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-160
• Table 96: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-160
• Table 97: Annual Sales Analysis: 2004-2005 (In US$ million) IV-160
• Table 98: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-160
• Table 99: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-161
• Biofluids/Invitrogen-Gibco (USA) IV-167
• Bioreliance Corporation (USA) IV-167
• Biosource International, Inc. (USA) IV-168
• Biosource Europe SA (Belgium) IV-169
• 62. Irvine Scientific, Inc. (USA) IV-170
• 63. Kemp Biotechnologies (USA) IV-171
• 64. Kimble Kontes Glass, Inc. (USA) IV-172
• 65. Leica Microsystems, Inc. (USA) IV-173
• 66. Mandel Scientific Company, Inc. (Canada) IV-176
• 67. Mediatech, Inc. (USA) IV-177
• 68. Medi-Cult A/S (Denmark) IV-178
• 69. Midwest Scientific (USA) IV-183
• 70. Millenium Biologix Corporation (USA) IV-184
• Table 100: First Quarter Sales Analysis: 2006-2007 (In US$ million) IV-185
• Table 101: First Quarter Sales Analysis by Segment: 2006-2007 (In US$ million) IV-185
• 71. Millipore Corporation (USA) IV-189
• Table 102: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-190
• Table 103: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-190
• Table 104: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ million) IV-190
• Table 105: Annual Sales Analysis: 2004-2005 (In US$ million) IV-190
• Table 106: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-190
• Table 107: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-191
• Table 108: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-191
• Celliance Corporation/Millipore' s Bioprocess Division (USA) IV-196
• 72. Minerva Biolabs GmbH (Germany) IV-198
• 73. MP Biomedicals (USA) IV-199
• 74. Nalge Nunc International, Inc. (USA) IV-201
• 75. New Brunswick Scientific Co., Inc. (USA) IV-202
• Table 109: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-203
• Table 110: Annual Sales Analysis: 2004-2005 (In US$ million) IV-203
• Table 111: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-203
• Table 112: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-203
• 76. Nikon Corporation (Japan) IV-206
• Table 113: Annual Sales Analysis: 2004-2006 (In ¥ million) IV-209
• Table 114: Annual Sales Analysis by Segment: 2005-2006 (In ¥ million) IV-209
• Table 115: Annual Sales Analysis by Geographic Region: 2005-2006 (In ¥ million) IV-209
• Table 116: Annual Sales Analysis by Segment: 2004-2005 (In ¥ million) IV-210
• Table 117: Annual Sales Analysis by Geographic Region: 2004-2005 (In ¥ million) IV-210
• 77. Osiris Therapeutics, Inc. (USA) IV-216
• Table 118: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-217
• 78. Pall Corporation (USA) IV-219
• Table 119: Annual Sales Analysis: 2004-2006 (In US$ million) IV-221
• Table 120: Annual Sales Analysis by Segment: 2005-2006 (In US$ million) IV-221
• Table 121: Annual Sales Analysis by Geographic Region: 2005-2006 (In US$ million) IV-221
• Table 122: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-221
• Table 123: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-222
• 79. Para Scientific Company (USA) IV-225
• 80. ProBioGen AG (Germany) IV-226
• 81. Promocell GmbH (Germany) IV-227
• 82. Quality Biological, Inc. (USA) IV-227
• 83. ReNeuron Ltd. (UK) IV-228
• 84. Rentschler Biotechnologie (Germany) IV-229
• 85. Research Organics, Inc. (USA) IV-230
• 86. Roche Molecular Biochemicals (USA) IV-230
• 87. Sartorius AG (Germany) IV-231
• Table 124: Annual Sales Analysis: 2004-2005 (In € million) IV-232
• Sartorius BBI Systems GmbH (Germany) IV-233
• Sartorius BBI Systems, Inc. (USA) IV-234
• Sartorius Vivascience GmbH (Germany) IV-234
• 88. SC Proven (UK) IV-235
• 89. Scientific Industries, Inc. (USA) IV-236
• Table 125: Annual Sales Analysis: 2005-2006 (In US$ thousands) IV-236
• 90. Sentigen Holding Corporation (USA) IV-238
• Table 126: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-239
• Table 127: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-239
• Table 128: Half Yearly Sales Analysis by Business Operation: 2005-2006 (H1) (In US$ million) IV-239
• Table 129: Annual Sales Analysis: 2004-2005 (In US$ million) IV-239
• Table 130: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-239
• Table 131: Annual Sales Analysis by Business Operation: 2004-2005 (In US$ million) IV-240
• Sentigen Biosciences (USA) IV-240
• Cell And Molecular Technologies, Inc. (USA) IV-241
• 91. Sera Laboratories International Ltd. (UK) IV-242
• 92. Serotec Ltd. (UK) IV-242
• 93. Sigma-Aldrich Corporation (USA) IV-243
• Table 132: First Quarter Sales Analysis: 2005-2006 (In US$ million) IV-244
• Table 133: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million) IV-244
• Table 134: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In US$ million) IV-244
• Table 135: Annual Sales Analysis: 2004-2005 (In US$ million) IV-244
• Table 136: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-244
• Table 137: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-245
• Table 138: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-245
• SAFC Biosciences (USA) IV-253
• Sigma-Aldrich Co., Ltd. (UK) IV-254
• 94. Spectrocell (USA) IV-255
• 95. Spectrum Laboratory Products Inc. (USA) IV-256
• 96. Stem Cell Sciences PLC (UK) IV-257
• Table 139: Half Yearly Sales Analysis: 2005-2006 (H1) (In £ million) IV-257
• 97. Stratagene, Inc. (USA) IV-259
• Table 140: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-261
• Table 141: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-261
• Table 142: Annual Sales Analysis: 2004-2005 (In US$ million) IV-261
• Table 143: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-261
• Table 144: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-261
• Table 145: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-262
• 98. Surmodics, Inc. (USA) IV-265
• Table 146: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-265
• Table 147: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-266
• Table 148: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million) IV-266
• Table 149: Annual Sales Analysis: 2004-2005 (In US$ million) IV-266
• Table 150: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-266
• Table 151: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-266
• 99. The Automation Partnership (TAP) (UK) IV-269
• 100. The Binding Site, Inc. (USA) IV-270
• 101. Thermo Fisher Scientific, Inc. (USA) IV-271
• Table 152: Annual Sales Analysis: 2004-2005 (In US$ million) IV-272
• Cole-Parmer Instrument Co. (USA) IV-277
• PerBio Science AB (Sweden) IV-279
• Hyclone Laboratories, Inc. (USA) IV-281
• 102. Thomas Scientific (USA) IV-283
• 103. USA Scientific, Inc. (USA) IV-283
• 104. USB Corporation (USA) IV-284
• Table 153: Annual Sales Analysis: 2004-2005 (In US$ million) IV-284
• 105. Ventria Bioscience (USA) IV-285
• 106. Vitrolife AB (Sweden) IV-286
• 107. Wave Biotech LLC (USA) IV-289
• 108. Whatman PLC (UK) IV-290
• Table 154: Half Yearly Sales Analysis: 2005-2006 (H1) (In £ million) IV-291
• Table 155: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In £ million) IV-291
• Table 156: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In £ million) IV-291
• Table 157: Annual Sales Analysis: 2004-2005 (In £ million) IV-291
• Table 158: Annual Sales Analysis by Segment: 2004-2005 (In £ million) IV-291
• Table 159: Annual Sales Analysis by Geographic Region: 2004-2005 (In £ million) IV-292
• 109. Wheaton Science Products (USA) IV-293
• 110. Wisent, Inc. (Canada) IV-293